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Abstract
Low vitamin D levels in human immunodeficiency virus type-1 (HIV) infected persons are associated with more rapid disease
progression and increased risk for Mycobacterium tuberculosis infection. We have previously shown that 1a,25-
dihydroxycholecalciferol (1,25D3), the active form of vitamin D, inhibits HIV replication in human macrophages through
the induction of autophagy. In this study, we report that physiological concentrations of 1,25D3 induce the production of
the human cathelicidin microbial peptide (CAMP) and autophagic flux in HIV and M. tuberculosis co-infected human
macrophages which inhibits mycobacterial growth and the replication of HIV. Using RNA interference for Beclin-1 and the
autophagy-related 5 homologue, combined with the chemical inhibitors of autophagic flux, bafilomycin A1, an inhibitor of
autophagosome-lysosome fusion and subsequent acidification, and SID 26681509 an inhibitor of the lysosome hydrolase
cathepsin L, we show that the 1,25D3-mediated inhibition of HIV replication and mycobacterial growth during single
infection or dual infection is dependent not only upon the induction of autophagy, but also through phagosomal
maturation. Moreover, through the use of RNA interference for CAMP, we demonstrate that cathelicidin is essential for the
1,25D3 induced autophagic flux and inhibition of HIV replication and mycobacterial growth. The present findings provide a
biological explanation for the benefits and importance of vitamin D sufficiency in HIV and M. tuberculosis-infected persons,
and provide new insights into novel approaches to prevent and treat HIV infection and related opportunistic infections.
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Introduction
Human immunodeficiency virus type-1 (HIV) is a global health
problem that has infected 60 million people and caused 25 million
deaths worldwide. Currently, there are an estimated 33 million
people living with HIV including 2 million children. Despite the
immune defense mechanisms that the host deploys against HIV
and improved antiretroviral therapies, the virus persists in long
lived cells including resting T cells, macrophages and dendritic
cells. One-third of HIV-infected individuals are co-infected with
Mycobacterium tuberculosis, a leading cause of death among people
living with HIV. It has been proposed that the increase in M.
tuberculosis pathology associated with HIV infection is caused by the
disruption of the local immune response within the tuberculosis
granulomas, decreasing their ability to contain M. tuberculosis
leading to increased mycobacterial replication, dissemination and
clinical disease [1–5]. Several studies have linked vitamin D
deficiency (25-hydroxycholecalciferol (25D3) deficiency) with an
increased risk for susceptibility to tuberculosis and active disease
both in the presence [6] and absence of HIV infection [7–14]. Few
studies have examined the association between vitamin D status
and HIV disease progression and survival. However, the data
available suggest that HIV-infected individuals have lower levels of
25D3 and/or the vitamin D3 active metabolite, 1a,25-dihydrox-
ycholecalciferol (1,25D3) than uninfected individuals [15–21] with
the lowest concentrations found in persons with AIDS [19,20].
Additionally, women with low levels of 25D3 have an increased
risk of HIV disease progression [22] and infants born to HIV-
infected mothers with low 25D3 levels have an increased risk of
HIV infection and increased mortality [23]. Although 25D3 has
no direct anti-mycobacterial or antiretroviral effect, its hormonally
active form, 1,25D3, modulates the immune response and has
been shown to exert both anti-mycobacterial [24–27] and anti-
HIV effects [27,28] in vitro.
Macroautophagy (herein referred to as autophagy) is a
trafficking pathway whereby cytoplasmic constituents such as
sub-cellular organelles and microbial pathogens are engulfed by
autophagosomes which fuse with lysosomes, forming autolyso-
somes, degrading the engulfed components. As an obligatory
intracellular parasite, HIV survival is dependent upon its ability to
exploit host cell machinery for replication and dissemination and
to circumvent cellular processes that prevent its growth. During
infection, HIV down regulates Beclin-1 and microtubule-associat-
ed protein 1 light chain 3B (LC3B)-II, reducing both basal
autophagy and the numbers of autophagosomes per cell [29,30].
However, silencing of autophagy proteins inhibits HIV infection of
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the biogenesis of phagolysosomes, and persists and replicates in
macrophages within special immature phagosomes characterized
by the exclusion of the vacuolar H
+ ATPase and the absence of
lysosomal hydrolases. In this study, we investigated the effect of
1,25D3 on productive HIV and M. tuberculosis infection of
macrophages. We demonstrate that 1,25D3 inhibits HIV replica-
tion and mycobacterial growth using autophagic machinery.
Results
1,25D3 Inhibits HIV replication in human macrophages in
the presence of M. tuberculosis infection
Previous studies have demonstrated that physiological concen-
trations of 1,25D3 have indirect antimicrobial activity against M.
tuberculosis and HIV. However, to date, no study has assessed the
ability of physiological levels of 1,25D3 to inhibit HIV during M.
tuberculosis co-infection. Therefore, we initially assessed whether
1,25D3 inhibits HIV replication in macrophages by comparing
the extent to which 1,25D3 pre-treatment affects HIV p24 antigen
accumulation in the supernatants of macrophages that were
subsequently infected with HIV and/or M. tuberculosis. 1,25D3
induced a dose-dependent inhibition of HIV replication with
50 pmol/L being the minimum concentration required to
significantly inhibit HIV by day 7 (68% reduction; P=0.003;
Figure 1A), while 100 pmol/L, the concentration found in healthy
25D3-sufficient HIV-uninfected plasma, inhibited HIV by 82%
(P,0.001; Figure 1A). Moreover, 1,25D3 induced a dose-
dependent reduction in cells expressing HIV p17 (Figure 1A). In
the presence of M. tuberculosis co-infection, 1,25D3 also induced a
dose-dependent inhibition of HIV replication. The minimum dose
of 1,25D3 required to significantly inhibit HIV replication did not
change (54% reduction; P=0.005; Figure 1A) and the profile of
intracellular HIV p17 expression post-1,25D3 treatment was
similar to M. tuberculosis-unexposed cells (Figure 1A).
1,25D3 Inhibits M. tuberculosis in human macrophages
in the presence of HIV infection
To evaluate the capacity of 1,25D3 to suppress the mycobac-
terial growth in HIV-infected macrophages, MDM were infected
with M. tuberculosis H37Rv at infection ratios (M. tuberculosis:target
cell) of 8:1. Cells were then cultured for 7 d in the presence of
varying concentrations of 1,25D3 after which they were lysed and
the number of colony forming units (cfu) of M. tuberculosis in
macrophages enumerated. There were no statistically differences
observed in cfu at day 0. However, at day 7, 1,25D3 induced a
dose-dependent reduction in cfu counts that became significant at
50 pmol/L (P,0.001; Figure 1B). This observed effect was
dependent upon macrophage infection by M. tuberculosis as
1,25D3 had no effect on mycobacterial viability when grown in
cell culture media or Middlebrook 7H9 broth alone (data not
shown). Moreover, 1,25D3 also induced a dose-dependent
reduction in M. tuberculosis-positive cells as assessed by flow
cytometry (Figure 1B). The effect of HIV infection on the capacity
of macrophages to limit mycobacterial growth was next assessed.
Although the presence of HIV resulted in a slightly increased cfu
count at day 7, there were no significant differences both in cfu
count or in growth index (cfu day 7:cfu day 0) compared with M.
tuberculosis only treated cells. In the presence of HIV infection,
1,25D3 treatment was associated with a dose-dependent reduction
in mycobacterial viability that became statistically significant at
50 pmol/L, at which point the cfu count was less than at day 0
(8.9610
4 versus 7.5610
4 cfu/well; P=0.001; Figure 1B). Flow
cytometry also revealed that 100 pmol/L 1,25D3 significantly
inhibited mycobacterial growth (Figure 1B). Dilutions of the lysates
were also run in a Mycobacteria Growth Indicator Tube 960
apparatus (MGIT 960). 1,25D3 induced a dose-dependent
increase in time to positive (75 growth units) both in the presence
and in the absence of HIV infection indicating a smaller initial
mycobacterial count post 1,25D3 treatments (Figure 1C).
1,25D3 Induces autophagy in human macrophages in
the presence of M. tuberculosis and HIV-co-infection
It has previously been demonstrated that 1,25D3 induces
autophagy in human macrophages during infection with either
HIV or M. tuberculosis. However, no study has investigated the
effect of 1,25D3 on autophagy during co-infection. Therefore, the
ability of 1,25D3 to induce autophagy in HIV and M. tuberculosis
co-infected human macrophages was assessed. An established
molecular marker for the induction of autophagy is the degree of
LC3B lipidation [32]. During autophagy, cytosolic LC3B-I is
converted to LC3B-II by a ubiquitin-like system that involves
autophagy related protein-7 (ATG7), ATG3 and the ATG5-
ATG12 complex. The ATG5-ATG12 complex ligates LC3B-II to
the nascent autophagosome membrane through phosphatidyleth-
anolamine with the LC3B-II associated with the inner membrane
degraded after fusion of the autophagosome with lysosomes.
Therefore, the conversion of LC3B-I to LC3B-II and its turnover
is an indicator of autophagy induction and flux [32]. 1,25D3
treatment of MDM induced an increase in LC3B-II in cells that
were incubated with HIV and/or M. tuberculosis (Figure 2A). The
accumulation of LC3B-II was increased in the presence of the
lysosomal protease inhibitor pepstatin A regardless of infection
status (Figure 2B), indicative of autophagic flux [33].
When autophagosomes are formed, LC3B redistributes from a
soluble diffuse cytosolic pattern to an insoluble autophagosome-
associated vacuolar pattern [34,35] allowing the quantification of
autophagosome-associated LC3B-II in human macrophages using
saponin resistance and flow cytometry [35]. Staining for endog-
Author Summary
Macroautophagy (autophagy - ‘self-eating’, lysosome-
dependent degradation and recycling of the intracellular
components in response to stress) is an important host
defense mechanism against viral and mycobacterial
infections. Recent studies have described that activation
of autophagy in macrophages reduces the viability of
Mycobacterium tuberculosis and HIV due to an intimate
autophagy-phagocytosis interaction. Low serum levels of
the 25-hydroxycholecalciferol form of vitamin D have been
associated with an increased risk for active tuberculosis
and HIV disease progression as well as M. tuberculosis
susceptibility. In this study, we report that the active form
of vitamin D, 1a,25-dihydroxycholecalciferol inhibits the
replication of HIV and M. tuberculosis in a concentration
dependent manner. Moreover, by inhibiting key stages in
the autophagy pathway, we demonstrate that the inhibi-
tion of HIV and mycobacterial growth during single
infection or dual infection is dependent not only upon
the induction of autophagy, but also through phagosomal
maturation. Furthermore, through the use of RNA inter-
ference for the human cathelicidin microbial peptide we
demonstrate that cathelicidin is essential for the 1a,25-
dihydroxycholecalciferol induced autophagic flux and
inhibition of HIV replication and mycobacterial growth.
These findings suggest that the induction of autophagy
has the potential to be useful in the treatment of persons
co-infected with HIV and M. tuberculosis.
HIV and M. tuberculosis Inhibition by Vitamin D and Autophagy
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percentage of cells containing a saponin resistant fraction
significantly increased with dose of 1,25D3 (P,0.05; Figure 2C).
In uninfected cells and in HIV and/or M. tuberculosis infected cells,
co-treatment with pepstatin A significantly increased the percent-
age and fluorescent signal of cells containing a saponin resistant
fraction upon treatment with 100 pmol/L 1,25D3 indicative of
autophagic flux (P,0.05; Figure 2D). Another control to confirm
that the increase in LC3B-II observed in 1,25D3 treated cells
during HIV and/or M. tuberculosis infection represents increased
autophagic flux, rather than an accumulation of LC3-positive
autophagosomes is the measurement of polyubiquitin-binding
protein p62 (sequestosome 1) degradation through immunoblot-
ting as p62 binds LC3B [33]. Inhibition of autophagy leads to an
increase in p62 protein levels while p62- and LC3-positive bodies
are degraded in autolysosomes during autophagic flux [36]. HIV
and/or M. tuberculosis infected MDM were subjected to 1,25D3
stimulus for 7 d after which p62 protein levels were measured by
western blot analysis. 1,25D3 treatment induced a decrease in p62
protein levels in HIV and/or M. tuberculosis infected MDM
compared to vehicle-treated cells, corresponding to a stimulation
of autophagic flux (Figure 2E).
Although there was an increase in autophagic markers in the
absence of visible pyknosis, karyorrhexis, or plasma membrane
blebbing, it was important to confirm that the cells were not
undergoing cell death at the physiological concentrations being
used, as the induction of excessive autophagy can cause cell death
in mammalian cells in experimental systems in vitro [37].
Therefore, plasma membrane breakdown (as a sign of cytotoxicity)
using the lactate dehydrogenase assay was measured in combina-
tion with the WST-1 assay that measures the activity of the
mitochondrial respiratory chain (as an indicator of viable cells).
After 7 d at physiological concentrations, 1,25D3 exhibited no
cytotoxic effects in the presence or absence of HIV and/or M.
tuberculosis infection (P.0.05; Figure 2F).
1,25D3-Mediated autophagy inhibits the replication of
HIV and M. tuberculosis in co-infected macrophages
Recent studies have demonstrated that physiological levels of
1,25D3 inhibit M. tuberculosis [38] and HIV [28] through
Figure 1. 1,25D3 inhibits HIV and M. tuberculosis replication. MDM were incubated with 1,25D3 for 4 h before infection with HIV and/or M.
tuberculosis (TB) for 3 h, washed then incubated with or without 1,25D3 for 7 days. (A) Top, extracellular release of HIV p24 antigen into the cell
supernatant at days 0, 4 and 7 was detected by ELISA. Bottom, MDM were harvested and stained for HIV p17. Histograms are shown for a
representative donor. (B) Top, cells were lysed after 3 h exposure to infectious agents or at the completion of the infection phase. Intracellular
mycobacteria were harvested and assayed for mycobacterial growth at day 0 and day 7. Bottom, MDM were harvested and stained for
mycobacterium. Histograms are shown for a representative donor. (C) Cell lysates from panel B were diluted and run in a MGIT 960. Bar and line
graphs are reported as mean 6 s.e.m. of three independent experiments performed in triplicate. 1 P,0.05; * P,0.001.
doi:10.1371/journal.ppat.1002689.g001
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investigate the relationship between infection status and the
1,25D3-mediated induction of autophagy. At 7 d post- HIV
infection, the majority of MDM were positive for HIV p17
(Figure 3A). Treatment with 100 pmol/L 1,25D3, reduced the
number of cells with detectable HIV p17 and was accompanied by
an overall reduction in mean HIV p17 antibody fluorescence that
was greatest in cells that also exhibited saponin resistant LC3B-II
(Figure 3A). In the absence of 1,25D3 and HIV infection,
incubation of MDM with M. tuberculosis for 7 days resulted in 75%
of MDM becoming positive for M. tuberculosis, one third of which
were also positive for saponin resistant LC3B-II (Figure 3B). All M.
tuberculosis negative cells were saponin resistant LC3B-II negative.
100 pmol/L 1,25D3 significantly decreased the number of M.
tuberculosis positive cells (P=0.002; Figure 3B) while concomitantly
increasing the number of saponin resistant LC3B-II positive cells.
Co-culture of MDM with both HIV and M. tuberculosis for 7 days
resulted in the inhibition of saponin resistant LC3B-II that
appeared in M. tuberculosis-only infected MDM. Similar to HIV
and M. tuberculosis-only infections, incubation with 100 pmol/L
1,25D3 increased the numbers of saponin resistant LC3B-II
positive cells while reducing the number of M. tuberculosis positive
Figure 2. 1,25D3 induces autophagy in human macrophages co-infected with HIV and M. tuberculosis. HIV and/or M. tuberculosis (TB)
infected MDM were treated for 7 days with 100 pmol/L 1,25D3. (A) Cells were lysed and immunoblots of LC3B isoforms using antibody to LC3B or b-
actin performed. (B) Cells were incubated with 10 mg/mL pepstatin A for 4 h on day 7 prior to lysis. Immunoblots of LC3B isoforms using antibody to
LC3B or b-actin. (C) Flow cytometry analysis of saponin-resistant LC3B-II in macrophages after 1,25D3 treatment for 7 d. Representative histograms of
cells displaying saponin-resistant LC3B-II from three donors are shown. (D) Flow cytometry analysis of saponin-resistant LC3B-II in macrophages after
1,25D3 treatment for 7 d followed by 10 mg/mL pepstatin A for a further 4 h. Representative histograms of cells displaying saponin-resistant LC3B-II
from three donors are shown. (E) Immunoblots of p62 using antibody to p62 or b-actin 7 d after macrophages treated with 1,25D3. (F) At 7 d post-
infection, aliquots of supernatant taken before the addition of WST-1 were tested for lactate dehydrogenase (LDH) spectrophotometrically using the
LDH
PLUS assay. For the last hour cells were incubated with WST-1, and the reduction of the WST-1 reagent to its formazan product was monitored
spectrophotometrically.
doi:10.1371/journal.ppat.1002689.g002
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infected with HIV/M. tuberculosis demonstrated saponin resistant
LC3B-II when treated with 50 pmol/L 1,25 D3, while cells
infected with HIV did not show saponin resistant LC3B-II when
treated with 50 pmol/L 1,25 D3. (Figure 3D).
The contribution of 1,25D3-induced autophagy in 1,25D3-
mediated inhibition of HIV and mycobacterial growth was
investigated by inhibiting sequential steps of the autophagy
pathway. As the physical interaction of class III phosphatidylino-
sitol 3-kinase with Beclin-1 forms the phosphatidylinositol 3-kinase
class III kinase complex and this complex is essential for the
induction of autophagosome formation at the vesicle elongation
step, RNAi for Beclin-1 was initially employed. Concomitant with
the findings that HIV utilizes autophagic machinery for replication
[28,31,39], the supernatant p24 antigen concentration in Beclin-1
silenced cells was decreased in the absence of 1,25D3 regardless of
M. tuberculosis infection status. In the absence of M. tuberculosis
infection, Beclin-1 silencing (Figure 4A) significantly reversed the
1,25D3 mediated inhibition of HIV at day 7 from 91% to 44%
(P,0.001; Figure 4B). Conversely, in the presence of M. tuberculosis
infection, Beclin-1 silencing reduced 1,25D3 inhibition of HIV
infection from 88% to 15% (P,0.001; Figure 4B).
In the absence of HIV, Beclin-1 silencing increased mycobac-
terial growth 51% at day 7 increase compared with the scrambled
non-target control RNAi treated cells (P=0.0006). HIV co-
infection increased this difference to 55% (P,0.001) although the
difference between the cfu counts between the M. tuberculosis and
HIV/M. tuberculosis treated Beclin-1 RNAi transduced cells was
not significant (P=0.36). The effect of 1,25D3 on the capacity of
macrophages to limit mycobacterial growth was next assessed.
Beclin-1 silencing protected against the anti-mycobacterial effects
of 1,25D3 both in the presence and in the absence of HIV
infection (P.0.05; Figure 4C). A similar profile was observed using
the MGIT 960 (Figure 4D).
During autophagy, cytosolic LC3B-I is converted to LC3B-II by
an ubiquitin-like system that involves the autophagy-related 7
(ATG7) homologue, ATG3 and the ATG5-ATG12 complex. The
ATG5-ATG12 complex ligates LC3B-II to the nascent autopha-
gosome membrane through phosphatidylethanolamine. There-
fore, RNAi of ATG5 inhibits autophagosome formation. In
agreement with the above findings that HIV was inhibited through
Beclin-1 silencing, ATG5 silencing (Figure 5A) also had an
inhibitory effect on HIV replication alone and in the presence of
M. tuberculosis co-infection (Figure 5B). In the absence of M.
Figure 3. 1,25D3 induces autophagy in human macrophages co-infected with HIV and M. tuberculosis. HIV (A), M. tuberculosis (TB) (B),
and HIV/TB dual infected MDM (C) were treated for 7 days with 100 pmol/L 1,25D3, harvested and stained for HIV p17, mycobacteria, and saponin-
resistant LC3B-II. Representative density plots from three donors are shown. (D) HIV/M. tuberculosis infected MDM (C) were treated for 7 days with
100 pmol/L 1,25D3, harvested and stained for HIV p17, mycobacteria, and saponin-resistant LC3B-II. Left, representative density plots from three
donors from HIV/M. tuberculosis infected MDM are shown for HIV/M. tuberculosis co-infection. Right, histograms of saponin-resistant LC3B-II in




+ at day 7 post-infection.
doi:10.1371/journal.ppat.1002689.g003
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1,25D3 mediated inhibition of HIV by day 7 (P,0.001; Figure 5B).
In the presence of M. tuberculosis co-infection, ATG5 silencing
reduced the 1,25D3 mediated inhibition of HIV at day 7 from
91% to 4% (P,0.001; Figure 5B). As for Beclin-1 RNAi, M.
tuberculosis growth was significantly increased in HIV infected and
uninfected ATG5 silenced cells in the absence of 1,25D3
treatment (P,0.003; Figure 5C). Moreover, the effect of 1,25D3
on the capacity of macrophages to limit mycobacterial growth was
severely diminished both in the presence and absence of HIV
infection (P,0.001; Figure 5C). A similar profile was observed
using the MGIT 960. ATG5 RNAi abrogated the 1,25D3
inhibition of mycobacterial growth both in the absence and
presence of HIV infection (Figure 5D).
We next investigated whether autophagosome acidification, a
late stage event during autophagy, is required for the 1,25D3-
mediated autophagic inhibition of HIV and M. tuberculosis. During
autophagy, lysosomes fuse with autophagosomes to form autop-
hagolysosomes. Macrophages were treated with bafilomycin A1,
an inhibitor of the vacuolar H
+ ATPase and thus autophagosome-
lysosome fusion, and subsequently infected with HIV and/or M.
tuberculosis. Bafilomycin A1 modestly increased HIV production
over 7 d in the absence of 1,25D3 and M. tuberculosis infection
although this was not significant. It had no effect on HIV
replication in the presence of M. tuberculosis infection. In the
presence of 1,25D3, bafilomycin A1 abrogated the 1,25D3-
mediated inhibition of HIV both alone and in the presence of
M. tuberculosis (Figure 6A). Mycobacterial growth was similarly
increased after bafilomycin A1 treatment in the absence of 1,25D3
in both infection models although this was not significant.
Bafilomycin A1 significantly reduced the inhibitory effect of
100 pmol/L 1,25D3 both in the presence (P=0.05; Figure 6B)
and absence of HIV co-infection (P=0.06; Figure 6B). We
obtained comparable results using the MGIT 960 with 100 pmol/
L 1,25D3 significantly inhibiting mycobacterial growth both in the
presence and absence of HIV infection (P,0.0001; Figure 6C).
These results suggest that the acidic pH of autophagolysosomes is
required for the autophagy-mediated control of both HIV
replication and M. tuberculosis growth by 1,25D3.
After lysosomes fuse with autophagosomes to form autophago-
lysosomes, the sequestered components are then degraded by
lysosomal hydrolases and presumably released into the cytosol by
Figure 4. 1,25D3 inhibition of HIV and M. tuberculosis is Beclin-1 dependent. MDM were transduced with non-specific scrambled shRNA
(shNS) or Beclin-1 shRNA (shBCLN1) and selected using puromycin resistance. Five days later, cells were incubated with 100 pmol/L 1,25D3 or vehicle
control for 4 h before infection with HIV and/or M. tuberculosis (TB) for 3 h. Cells were then washed and incubated with 100 pmol/L 1,25D3 or vehicle
control for 7 days. (A) Immunoblot analysis performed using antibodies raised to Beclin-1 or b-actin after initial pathogen exposure (Day 0) or after 7
days. (B) ELISA performed for HIV p24 antigen release over 7 d. (C) Intracellular mycobacteria were harvested and assayed for mycobacterial growth
by cfu enumeration at day 0 and day 7. (D) Intracellular mycobacteria harvested and assayed for viability based on time to positivity (75 growth units)
at day 0 and day 7 using the MGIT 960. All bar and line graphs are reported as mean 6 s.e.m. of three independent experiments performed in
triplicate. 1 P,0.05; * P,0.001.
doi:10.1371/journal.ppat.1002689.g004
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hydrolases in 1,25D3-mediated inhibition of HIV and M.
tuberculosis through autophagy was examined using SID
26681509, a novel thiocarbazate specific inhibitor of the lysosome
hydrolase cathepsin L. In the absence of 1,25D3 there was no net
inhibition of either HIV or M. tuberculosis growth (Figure 7A).
Moreover, in the presence of 1,25D3, SID 26681509 abrogated
the inhibition of both HIV and M. tuberculosis (Figure 7B and 7C).
Together, these data indicate that the 1,25D3-mediated induction
of autophagy in macrophages inhibits HIV and M. tuberculosis
replication regardless of co-infection status.
1,25D3-Mediated autophagy and inhibition of HIV and M.
tuberculosis is dependent upon the expression of human
cathelicidin microbial peptide
Previous studies have demonstrated that the human cathelicidin
microbial peptide (CAMP) is required for the 1,25D3 mediated
antimycobacterial activity against M. tuberculosis [38,40] and the
1,25D3-mediated autophagy in human macrophages [38]. To
address the role of CAMP in 1,25D3-induced antimicrobial
activity, RNAi for CAMP was employed. Transduction of
shCAMP into MDM completely silenced the 1,25D3-induced
expression of CAMP during HIV and M. tuberculosis co-infection
(Figure 8A). Moreover, CAMP silencing markedly inhibited
1,25D3-induced autophagy, whereas MDM transduced with a
scrambled (shNS) showed increased saponin resistant LC3,
consistent with autophagosome formation. Concomitant with
our findings that autophagy is required for the restriction of
HIV replication, CAMP silencing reduced 1,25D3 inhibition of
HIV both alone (90% shNS versus 10% shCAMP; P,0.001;
Figure 8C) and in the presence of M. tuberculosis infection (91%
shNS versus 10% shCAMP; P,0.001; Figure 8C). Moreover,
CAMP silencing completely blocked the 1,25D3-mediated anti-
mycobacterial activity (P,0.001; Figure 8D). These data suggest
that CAMP is required for 1,25D3-mediated antimicrobial activity
against both intracellular M. tuberculosis and HIV in human MDM.
Discussion
Despite much progress in the care and treatment of persons
infected with HIV and those suffering from tuberculosis, the two
pathogens are inextricably linked as important causes of morbidity
and mortality worldwide. Thus, the effective treatment of persons
Figure 5. 1,25D3 inhibition of HIV and M. tuberculosis is ATG5 dependent. MDM were transduced with non-specific scrambled shRNA (shNS)
or ATG5 shRNA (shATG5) and selected using puromycin resistance. Five days later, cells were incubated with 100 pmol/L 1,25D3 or vehicle control for
4 h before infection with HIV and/or M. tuberculosis (TB) for 3 h. Cells were then washed and incubated with 100 pmol/L 1,25D3 or vehicle control for
7 days. (A) Immunoblot analysis performed using antibodies raised to ATG5 or b-actin after initial pathogen exposure (Day 0) or after 7 days. (B) ELISA
performed for HIV p24 antigen release over 7 d. (C) Intracellular mycobacteria were harvested and assayed for mycobacterial growth by cfu
enumeration at day 0 and day 7. (D) Intracellular mycobacteria harvested and assayed for viability based on time to positivity (75 growth units) at day
0 and day 7 using the MGIT 960. All bar and line graphs are reported as mean 6 s.e.m. of three independent experiments performed in triplicate. 1
P,0.05; * P,0.001.
doi:10.1371/journal.ppat.1002689.g005
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challenge. In the case of tuberculosis, administration of vitamin D
and/or sunlight exposure has a long and colorful history [11]. In
fact, the beneficial effects of cod liver oil in the treatment of
tuberculosis were first recognized in 1849 and Niels Finsen
received the Nobel Prize in 1903 for his discovery of ultra-violet
light as an effective therapy for the cutaneous form of tuberculosis,
lupus vulgaris. However, more than 100 years later, the
therapeutic benefits of vitamin D and the plasma levels of 25D3
required to provide clinical benefit remain controversial [41,42].
Our results demonstrate that physiological concentrations of
1,25D3 inhibit both HIV and M. tuberculosis replication in human
macrophages through an autophagy and CAMP dependent
mechanism, and that 1,25D3 can act as a potent stimulator of
innate antimicrobial responses. The ability of macrophages to kill
intracellular pathogens is pivotal to the outcome of microbial
infections. Within macrophages, M. tuberculosis and HIV reside in
phagosomes and evade host microbial mechanisms by blocking
phagosome maturation and fusion with lysosomes [39,43].
However, the host can overcome this block through the induction
of autophagy [28,44,45]. Previous studies have shown that
physiological concentrations of 1,25D3 mediate the induction of
autophagy and the individual killing of M. tuberculosis [38] and HIV
[28]. To our knowledge the present study is the first to
demonstrate that 1,25D3 inhibits both M. tuberculosis and HIV
co-infection of macrophages through the induction of autophagy
mediated by CAMP.
The in vitro findings reported here are supported by association
studies that have linked low levels of 25D3 and/or 1,25D3 with
increased risk of, or severity of infection with HIV [15–23] and M.
tuberculosis [7–10,12–14,21]. Why HIV-infected individuals tend to
have lower levels of 1,25D3 and/or 25D3 is largely unknown but
is thought to be related to inadequate renal 1a-hydroxylation
mediated by pro-inflammatory cytokines and/or a direct effect of
Figure 6. Bafilomycin A1 inhibits the 1,25D3 mediated inhibition of HIV and M. tuberculosis replication. MDM were pretreated with
bafilomycin A1 (Baf A1) before treatment with 1,25D3 and subsequent infection with HIV and/or M. tuberculosis (TB). (A) ELISA performed for HIV p24
antigen release at days 0, 4 and 7. (B) Intracellular mycobacteria were harvested and assayed for mycobacterial growth by cfu enumeration at day 0
and 7. (C) Intracellular mycobacteria harvested and assayed for viability using the MGIT 960 based on time to positivity at day 0 and 7. All bar and line
graphs are reported as mean 6 s.e.m. of three independent experiments performed in triplicate. 1 P,0.05; * P,0.01.
doi:10.1371/journal.ppat.1002689.g006
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on 1,25D3 and/or 25D3 syntheses have not been evaluated.
Vitamin D deficiency is conservatively defined by most experts as
,50 nmol/L 25D3 [47]; 52–72 nmol/L 25D3 is considered to
indicate insufficiency and .73 nmol/L considered sufficient [47].
In contrast to this, the estimated mean concentration of 25D3
present in people worldwide is just 54 nmol/L [48]. Four genes
are known to contribute to the variability of serum 25D3
concentrations: 7-dehydrocholesterol reductase (involved in cho-
lesterol synthesis and the availability of 7-dehydrocholesterol in the
skin), 25-hydroxylase CYP2R1 (cytochrome P450, family 2,
subfamily R, polypeptide 1) and CYP24A1 (cytochrome P450,
family 24, subfamily A, polypeptide 1) (degrades and recycles
1,25D3) and GC (group-specific component [vitamin D binding
protein]) which encodes for the vitamin D binding protein.
Genetic variations at these loci were recently identified to be
significantly associated with an increased risk of 25D3 insufficiency
[49].
A better understanding of the pathogenesis of tuberculosis will be
necessary if novel interventions are to be developed to effectively
treat persons infected with M. tuberculosis and HIV. The induction of
autophagy to enhance treatment is attractive for a number reasons
including: 1) autophagy would work at the cellular level to improve
intracellular killing of both pathogens; 2) enhanced autophagy is
likely to be equally active against multi-drug resistant (MDR) and
extensively drug resistant (XDR) M. tuberculosis as it is against drug
sensitiveM.tuberculosis;3)autophagyhasthe potentialtoinhibit non-
replicating HIV and M. tuberculosis within endosomes; 4) autophagy
promotes innate and adaptive immunity; and 5) HIV or M.
tuberculosis resistance is unlikely to develop.
The characterization of the 1,25D3 mediated antimicrobial
mechanism in macrophages provides further evidence of the link
between vitamin D and the immune system. The intracrine nature
of this mechanism suggests that the ability of 25D3 to promote M.
tuberculosis and HIV killing could be affected by the efficiency of the
synthesis of 1,25D3 by macrophages. Unlike the parathyroid-
Figure 7. SID 26681509 inhibits the 1,25D3 mediated inhibition of HIV and M. tuberculosis replication. MDM were pretreated with SID
26681509 (SID) before treatment with 1,25D3 and subsequent infection with HIV and/or M. tuberculosis (TB). (A) ELISA performed for HIV p24 antigen
release at days 0, 4 and 7. (B) Intracellular mycobacteria were harvested and assayed for mycobacterial growth by cfu enumeration at day 0 and 7. (C)
Intracellular mycobacteria harvested and assayed for viability using the MGIT 960 based on time to positivity at day 0 and 7. All bar and line graphs
are reported as mean 6 s.e.m. of three independent experiments performed in triplicate. 1 P,0.05; * P,0.01.
doi:10.1371/journal.ppat.1002689.g007
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subfamily B, polypeptide 1 (CYP27B1), extra-renal CYP27B1 is
not subject to the same feedback control so that the local synthesis
of 1,25D3 in macrophages probably reflects the availability of
25D3. Toll-like receptor 2/1 agonists and interferon gamma
upregulate the expression of the CYP27B1 which 1a-hydroxylates
25D3 into 1,25D3, activating and upregulating the expression of
the vitamin D (1,25D3) receptor (VDR) leading to the induction of
CAMP and autophagic flux [50,51]. When serum is 25D3
deficient, TLR2/1 agonists (,25 nmol/L) [50] and interferon
gamma (,45 nmol/L) [51] are unable to induce the expression of
CAMP from monocytes or macrophage.
In the present study we demonstrate that the 1,25D3-induced
autophagy and anti-mycobacterial activity was dependent on the
expression of endogenous CAMP in agreement with previous
findings [38]. Moreover, by using RNAi for CAMP we demon-
strate, for the first time, that the 1,25D3 induced autophagy and
subsequent autophagy-induced antiretroviral activity is dependent
upon endogenous CAMP expression. This finding highlights the
importance of endogenous CAMP during autophagy induction and
antiretroviral activity. High concentrations of exogenous synthetic
cleaved form of CAMP (LL-37) have been shown to reduce
mycobacterial growth [25,38,40] and HIV replication [28].
However, at the much lower concentrations secreted in vitro by
1,25D3 treated macrophages, exogenously added LL-37 has not
been shown to have an inhibitory effect on either organism [25,28]
or induce the formation of autophagosomes [28]. However, Yuk et
al. [38] clearly showed that CAMP is upstream of Beclin-1 and
ATG5 induction post-1,25D3 treatment and we show that in
CAMP silenced cells 1,25D3 fails to induce LC3B lipidation.
Further work is necessary to determine the precise role CAMP has
in 1,25D3 induced autophagy and antimicrobial activity.
When modeling the replication of mycobacteria in human cells,
we used the standard protocol of incubating macrophages with M.
tuberculosis followed by washing the cells of non-phagocytosed bacilli.
In this way, the intracellular replication of mycobacteria in
macrophages can be assessed. However, M. tuberculosis is able to
replicate extracellularly in vivo and as would be expected, we
observed that 1,25D3 had no effect on M. tuberculosis survival in the
extracellular compartment. In addition, as the cfu assay is
cumbersome for high-throughput analyses, we adopted and ran
samples in the MGIT 960 using a standard curve derived from the
untreated macrophage cell lysates and found that the results
obtained with this method were closely aligned with those obtained
using the more subjective cfu method. This procedure can be used
to more rapidly and efficiently screen compounds for the ability to
inhibit M. tuberculosis replication compared to the standard assay.
In summary, this study establishes a role for autophagy during
the early phases of HIV infection and demonstrates that the
induction of autophagy by 1,25D3 can inhibit HIV and M.
tuberculosis co-infection in macrophages. Well-controlled clinical
trials are needed to determine if vitamin D supplementation is of
value for prevention or as adjunctive treatment in HIV-infected
persons against active tuberculosis. Dissecting the molecular
mechanisms by which HIV and M. tuberculosis utilize autophagy
has the potential to lead to the identification of novel drug
candidates that can be used to prevent and treat HIV infection
and related opportunistic infections including tuberculosis.
Materials and Methods
Ethics statement
Venous blood was drawn from HIV seronegative subjects using
a protocol that was reviewed and approved by the Human
Figure 8. Inhibition of HIV and M. tuberculosis by 1,25D3 is
CAMP and autophagy dependent. MDM were transduced with
non-specific scrambled shRNA (shNS) or CAMP shRNA (shCAMP) and
selected using puromycin resistance. Five days later, cells were
incubated with 100 pmol/L 1,25D3 or vehicle control for 4 h before
infection with HIV and/or M. tuberculosis (TB) for 3 h. Cells were then
washed and incubated with 100 pmol/L 1,25D3 or vehicle control for 7
days. (A) Immunoblot analysis performed using antibodies raised to
CAMP or b-actin after initial pathogen exposure (Day 0) or after 7 days.
(B) Day 7 HIV-1Ba-L and TB co-infected cells were harvested and stained
for saponin-resistant LC3B-II at day 7. A representative histogram from
three donors are shown. (C) ELISA performed for HIV p24 antigen
release over 7 d. (D) Intracellular mycobacteria were harvested and
assayed for mycobacterial growth by cfu enumeration at day 0 and day
7. All bar and line graphs are reported as mean 6 s.e.m. of three
independent experiments performed in triplicate. * P,0.001.
doi:10.1371/journal.ppat.1002689.g008
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Diego (Project 08-1613) in accordance with the requirements of
the Code of Federal Regulations on the Protection of Human
Subjects (45 CFR 46 and 21 CFR 50 and 56). All human studies
were conducted according to the principles expressed in the
Declaration of Helsinki. Written informed consent was obtained
from all study participants prior to their participation.
Isolation and cultivation of human monocyte derived
macrophages
Peripheral blood mononuclear cells were isolated from whole
blood by density gradient centrifugation over Ficoll-Paque Plus
(GE Healthcare). Cells were then incubated overnight at 37uC, 5%
CO2 in RPMI 1640 (Gibco) supplemented with 10% (v/v)
charcoal/dextran treated, heat-inactivated fetal bovine serum
(FBS; Gemini Bio-Products) and 10 ng/mL macrophage colony
stimulating factor (R&D Systems), after which non-adherent cells
were removed by aspiration. The same lot of FBS was used
throughout all experiments. Monocyte derived macrophages were
obtained by incubating the adherent population in the culture
medium at 37uC, 5% CO2 for a further 10 days. The recovered
cells were .95% CD163
+, as determined by flow cytometry.
Chemicals and inhibitors
1,25D3, pepstatin A, bafilomycin A1 and SID 26681509 were
purchased from Sigma. Bafilomycin A1 and SID 26681509 were
used at 100 and 50 nmol/L, respectively with pretreatment for 1 h
before addition of 1,25D3 or vehicle control. Cytotoxicity of the
different chemicals at the concentrations used was tested by the
trypan blue dye exclusion assay, and none was found to be
cytotoxic (viability was .99%).
shRNA Transduction
MISSION small hairpin (shRNA) lentiviral particles were
obtained from Sigma. Lentiviral transduction of MDMs with
particles for shRNAs targeting ATG5 (SHCLNV-NM_004849/
TRCN0000150940), Beclin-1 (SHCLNV-NM_003766/TRCN0
000033551), CAMP (SHCLNV-NM_004345/TRCN000011864
5), or scrambled non-target negative control (Scr, SHC002V) was
performed according to the manufacturer’s protocol. Electropho-
resis and immunoblotting was as previously described [28].
HIV and M. tuberculosis strains and growth conditions
HIVBa-L was obtained through the AIDS Research and
Reference Reagent Program, from Suzanne Gartner and Robert
Gallo [52,53]. Virus stocks were prepared and titered as previously
described using the Alliance HIV p24 antigen enzyme-linked
immunosorbent assay kit (ELISA; Perkin Elmer) [54]. M.
tuberculosis H37Rv was kindly provided by Janice Kaping,
University of California San Diego. Stock strains were grown for
7–10 days to reach mid-exponential growth phase in Middlebrook
7H9 broth supplemented with 1% glycerol, 0.05% polybrene 80
and 10% OADC (oleic acid, albumin, dextrose, catalase)
enrichment (all Sigma) at 37uC. Mycobacterial cultures were
pelleted at 30006g for 10 min and resuspended in Middlebrook
7H9 broth. Clumped mycobacteria were dispersed using ultra-
sound waves (3 to 5 min, 40 kHz; NeyTech). The sample was
centrifuged at 2006g for 10 min to pellet the clumped bacilli, and
the upper mycobacterial suspension was used in all experiments.
Cultures were plated for viable colony forming unit (cfu) counts on
Middlebrook 7H10 agar with OADC enrichment (BD Diagnostic
Systems). To rule out the influence of lipopolysaccharide (LPS) in
the assays, the mycobacterial suspensions were tested by the
Limulus amebocyte lysate assay (Lonza). The effective LPS
concentration was ,2 pg/mL in experiments with mycobacteria
to cell ratios of 8:1.
HIV and M. tuberculosis infection assay
5610
5 MDM were treated for 4 h with 1,25D3 then infected with
10
5 TCID50 HIVBa-L and/or 4610
6 M. tuberculosis for 4 h. After an
incubation period of 4 h, noningested M. tuberculosis were removed
by washing four times with DPBS. The majority of extracellular
mycobacteria (.99%)were removed with thisprocessasdetermined
by auramine-rhodamine staining. Each well was repleted with 1 mL
RPMI1640supplementedwith10%(v/v)heat-inactivatedFBSwith
or without 1,25D3, and incubated for 30 min (time 0) and 7 d. At
day 4, 500 mL cell supernatant was sampled a replaced with 500 mL
fresh media 61,25D3 added at this point. For RNAi experiments,
1610
5 MDM were used and volumes and infectious particles
adjusted accordingly. At the end of the incubation periods cells and
supernatants were harvested and stored frozen at 270uCu n t i l
further assessment in the p24 ELISA or the cfu assay.
To assess the number of intracellular mycobacteria, cells were
thawed and lysed with 0.5% (w/v) sodium dodecyl sulfate (Sigma).
Lysates of infected cells were resuspended vigorously, transferred into
screw caps and sonicated in a preheated (37uC) water bath sonicator
for 5 min (40 kHz; NeyTech). Aliquots of the lysates were diluted in
Middlebrook 7H9 broth and serial dilutions of each sample were
plated in quadruplicate on Middlebrook 7H10 agar with OADC
enrichment (BD Diagnostics) and incubated at 37uCa n d5 %C O 2for
30 days. CFU were enumerated using a stereomicroscope. The
results are expressed as mean 6 SE of CFU/well.
Alternatively, a dilution of each sample was placed into a Bactec
MGIT 960 (BD Diagnostics). Before inoculation, Bactec MGIT
960 tubes were supplemented as described by the manufacturer
(MGIT [7-ml] package insert; Becton Dickinson). The lysates were
diluted 1:40 in Middlebrook 7H9 and a 50 mL aliquot of this was
further diluted 1:10 in Middlebrook 7H9 and inoculated into the
MGIT tube (500 mL added). The tubes were introduced into the
Bactec MGIT 960 instrument, as recommended by the manufac-
turer and incubated either until they were found to be positive by
the instrument (75 Growth Units) or for 6 weeks. Results are
expressed as mean time to positivity.
Aliquots of the cell supernatants were taken for HIV p24
analysis by ELISA at days 0, 4 and 7. At all time points, an aliquot
of unlysed, infected cells was harvested, enumerated and viability
assessed using the trypan blue exclusion assay. Recovery of the
cells was .90% in all experiments, with cell viability exceeding
95% at all time points and treatments.
Flow cytometry. Intracellular staining of endogenous sapo-
nin resistant LC3B was performed as previously described [28,35]
using rabbit anti-LC3B (D11), mouse anti-Gag-p17 (2D11)
(Abcam) and chicken anti-M. tuberculosis antigen 85A (Sigma)
followed by allophycocyanin (APC) conjugated goat anti-rabbit
IgG, fluorescein isothiocyanate (FITC) conjugated goat anti-
mouse IgG1 and phycoerythrin (PE) conjugated goat anti-chicken
IgY (Santa Cruz Biotechnology).
Statistical analysis
Two-tailed, Student’s t tests, a=0.05, were used to assess
whether the means of two normally distributed groups differed
significantly.
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